8 October 2024
Eden Research
Plc
("Eden"
or "Company")
OTCQB exchange
update
Eden Research plc (AIM: EDEN), a
leader in sustainable biopesticide and biocontrol technology,
announces that it has, as of today, delisted from the OTCQB
exchange in the US.
Following a review of its capital
markets strategy, the Board of Eden has taken the decision to
delist the Company from the US-based OTCQB exchange in light of the
low trading activity of the Company's ordinary shares on that
exchange. The delisting will have no impact on the Company's
ordinary shares, which will continue to trade on AIM.
For further information
contact:
|
Eden
Research plc
|
|
|
Sean Smith
Alex Abrey
|
www.edenresearch.com
01285 359
555
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated advisor and
broker)
|
|
|
Giles Balleny / George
Lawson (corporate finance)
Charlie Combe (corporate broking)
Michael Johnson (sales)
|
020 7220
0500
|
|
|
|
|
Hawthorn Advisors (Financial PR)
|
|
|
Victoria Ainsworth
|
eden@hawthornadvisors.com
|
Notes to Editors:
Eden Research is the
only UK-listed company focused on biopesticides for
sustainable agriculture. It develops and supplies innovative
biopesticide products and natural microencapsulation technologies
to the global crop protection, animal health and consumer products
industries.
Eden's products are formulated with
terpene active ingredients, based on natural plant defence
metabolites. To date, they have been primarily used on high-value
fruits and vegetables, improving crop yields and marketability,
with equal or better performance when compared with conventional
pesticides. Eden has three products currently on the
market:
Based on plant-derived active
ingredients, Mevalone® is a foliar biofungicide which
initially targets a key disease affecting grapes and other
high-value fruit and vegetable crops. It is a useful
tool in crop defence programmes and is aligned with the
requirements of integrated pest management programmes. It is
approved for sale in a number of key countries whilst Eden and its
partners pursue regulatory clearance in new territories thereby
growing Eden's addressable market globally.
Cedroz™ is a
bionematicide that targets free living nematodes which are
parasitic worms that affect a wide range of high-value fruit and
vegetable crops globally. Cedroz is registered for sale on
two continents and Eden's commercial collaborator, Eastman
Chemical, is pursuing registration and commercialisation of this
important new product in numerous countries globally.
Eden's seed treatment
product, EcovelexÔ was developed to safely tackle crop destruction caused
by birds - a major cause of losses in maize and other
crops. Ecovelex works by creating an unpleasant taste or odour
that repels birds, leaving the seeds safely intact and the birds
unaffected and free to find alternative food sources. The
product is based on Eden's plant-derived chemistry, registered in
the EU, U.S. and elsewhere, and formulated using Eden's Sustaine®
microencapsulation system.
Eden's Sustaine® encapsulation
technology is used to harness the biocidal efficacy of naturally
occurring chemicals produced by plants (terpenes) and can also be
used with both natural and synthetic compounds to enhance their
performance and ease-of-use. Sustaine microcapsules are
naturally-derived, plastic-free, biodegradable micro-spheres
derived from yeast. It is one of the only viable, proven and
immediately registerable solutions to the microplastics problem in
formulations requiring encapsulation.
Eden was admitted to trading on AIM
on 11 May 2012 and trades under the symbol EDEN. It was
awarded the London Stock Exchange Green Economy Mark in January
2021, which recognises London-listed companies that derive
over 50% of their total annual revenue from products and services
that contribute to the global green economy. Eden derives 100% of
its total annual revenues from sustainable products and
services.
For more information about Eden,
please visit: www.edenresearch.com.